SpringLeaf Therapeutics develops technology intended to enable and differentiate biologic therapeutics through the convergence of materials science and medicine. Its platform uses an internally driven morphing surface as a compact power-and-delivery mechanism to administer highly viscous and large-volume (above one milliliter) biopharmaceuticals subcutaneously. The company’s prefilled system is designed for patient self-administration, aiming to reduce the need for complicated delivery systems, multiple injections, and outpatient visits. SpringLeaf intends to develop therapeutic products that increase patient convenience, adherence, and access while potentially lowering treatment costs and improving outcomes. The company was founded based on breakthrough science at MIT and is backed by investors including SR One, Flybridge Capital Partners, and North Bridge Venture Partners. Financially, SpringLeaf announced a second close of its Series B, adding $4 million from Excel Venture Management to bring the round to $19 million.

Total raised

$4M

Funding rounds

1

Latest round

Series B

Latest activity

Jul 2011